Skip to content
RSV, Virus RSV, Virus

Risk Factors and Clinical Burden of RSV in Older Adults

While RSV-related infections usually present as mild cold-like symptoms in adults, some cases may lead to more serious respiratory complications, hospitalization and death, particularly in older adults and those with underlying conditions1

Quicks links

Risk Factors

Risk factors for severe RSV disease in adults include

The risk of RSV- associated hospitalization increases with age.

RSV, Hospitalization

A large prospective study estimated the incidence of RSV-associated hospitalization in two regions of New York State, USA, 2017–2020. N=1099 cases:4

RSV, Graph, Hospitalization

This graph was independently created for GSK from the original data

Hospitalization rates for RSV were higher in adults with underlying conditions2

Comorbidity Incidence rate ratio*
  Rochester
NYC
COPD    
50-64y
6.35
6.30
≥65y
13.41
3.51
Asthma
   
50-64y 2.34 3.60
≥65y 2.52 2.27
Diabetes    
50-64y 3.36 3.58
≥65y 6.44 2.35
CAD    
50-64y 3.74 4.41
≥65y 6.46 3.75
CHF    
60-79y 7.63 5.86
≥80y 3.99 5.40

*Ratio of rate among people with each comorbidity versus those without it, in the surveillance area population

Burden of Disease

RSV can Cause Severe Complications in older adults

In older adults hospitalized with RSV, the risk of severe outcomes is comparable to those hospitalized with influenza

RSV, Complications, Adults, Graph

This graph was independently created for GSK from the original data

Economic Burden of RSV in Older Adults

RSV, Hospital

Learn more about RSV disease and its burden in adults:

Abbreviations

CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; NYC, New York City; RSV, respiratory syncytial virus

References

  1. CDC, 2020. RSV in older adults and adults with chronic medical conditions.https://www.cdc.gov/rsv/high-risk/older-adults.html. Accessed July 2022.
  2. Branche AR et al. Clin Infect Dis. 2022 Mar 23;74(6):1004-1011. doi: 10.1093/cid/ciab595
  3. Belongia EA et al. Open Forum Infect Dis 2018;27;5:ofy316.
  4. Walker E, Ison MG. Influenza Other Respir Viruses 2014;8:282–292.
  5. Ackerson B et al. Clin Infect Dis 2019;69:197–203.
  6. Lee N et al. Clin Infect Dis 2013; 57:1069–1077
  7. Troeger C et al. Lancet Infect Dis 2018;18:1191-1210.
  8. Falsey AR et al. N Engl J Med 2005;352:1749–1759.

Material supplied by the above-country business unit to LOCs for localisation must be subject to local Medical and/or Regulatory review and approval prior to use and/or external distribution.

LOCs to insert local adverse events reporting procedure.

©2023 GSK group of companies or its licensor. GlaxoSmithKline Biologicals SA. Rixensart, Belgium.

NX-GBL-RSA-WCNT-220003 | January 2023